|
Clinical results of a phase 1 trial evaluating a HER2 directed CAR-T product selective for the tumor microenvironment (TME) in patients with GI and other solid tumor malignancies. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Employment - Shanghai Perhum Therapeutics |
Leadership - Shanghai Perhum Therapeutics |
| |
|
Employment - Shanghai EXUMA Biotech |
Leadership - Shanghai EXUMA Biotech |
Stock and Other Ownership Interests - Shanghai EXUMA Biotech |
| |
|
Employment - Exuma Biotech |
Leadership - Exuma Biotech |
Stock and Other Ownership Interests - Exuma Biotech |
| |
|
No Relationships to Disclose |